Galectin Therapeutics
Mr. Freeman holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also the author of a New York Times bestselling book about the stock market and economy. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a B.S. in business administration from the University of Tulsa, Tulsa, Oklahoma.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Galectin Therapeutics
1 followers
Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.